A phase 2, multi-centre, randomised, doublemasked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

November 26, 2013

Participants must have documented dry age related macular degeneration with geographic atrophy. They must be willing and able to participate in this 2 year study consisting of observation and treatment. All eligibility criteria must be met.

Mary K. Monk